Cleveland Diagnostics’ IsoPSA test for prostate cancer detection gains FDA approval
Now a test that offers new precision in prostate cancer detection
Now a test that offers new precision in prostate cancer detection
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
GV20 received an upfront payment and is eligible for additional milestone payments
The fresh capital will propel Cordance into its first-in-human clinical trial
Subscribe To Our Newsletter & Stay Updated